ALN-BCAT Overview

An Investigational RNAi Therapeutic

Disease State(s) Under Investigation	Hepatocellular carcinoma (HCC)[1]
MoA	Designed to target production of β-catenin in the liver[2]
Route of Administration	Intravenous[1]

Clinical Trials Overview

Phase 1	Treatment Arms	Primary Endpoint
Recruiting		
Safety and Tolerability of **ALN-BCAT** as **Monotherapy** and in **Combination** with Pembrolizumab Adult Patients with Advanced or Metastatic HCC[1]	Monotherapy: ALN-BCAT Combination: ALN-BCAT + pembrolizumab	Efficacy (antitumor activity as assessed by RECIST v1.1) Safety and tolerability (frequency/severity of AEs; occurrence of DLTs)

The safety and efficacy of ALN-BCAT has not been established by any health authority.

AE, adverse event; DLT, dose-limiting toxicity; HCC, hepatocellular carcinoma; MoA, mechanism of action; RECIST, Response Evaluation Criteria in Solid Tumors; RNA, ribonucleic acid; RNAi, RNA interference.

1. ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT06600321 (Accessed February 17, 2026). 2. Dadali T et al. Cancer Res 2024;84(6 Suppl):5924.

Alnylam